This inventor holds 21 USPTO granted patents and 4 published patent applications, plus 6 CIPO patents and 8 EPO patents, primarily in Receptor Agonists. Top assignees: Research Triangle Institute, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2011-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Hillsborough, NC (US) (2013 - 2023)
- Research Triangle Park, NC (US) (2011 - 2024)
Company Filing History:
21 out of 359 
3 out of 3,696 
Years Active: 2011-2026
Areas of Expertise:
Title: Scott P. Runyon: Innovator in Apelin Receptor Agonists
Introduction
Scott P. Runyon, based in Hillsborough, NC, is a prominent innovator with a remarkable portfolio of 19 patents. His work primarily revolves around the development of novel compounds that target the apelin receptor, a crucial component in various physiological processes.
Latest Patents
Runyon's recent patents include significant advancements in the field of pharmacology. Notably, he has developed two related disclosures titled "Heterocyclic Apelin Receptor (APJ) Agonists and Uses Thereof" and "Apelin Receptor (APJ) Agonists and Uses Thereof." These disclosures focus on agonists with heterocyclic cores designed to enhance the functionality of the apelin receptor, showcasing their potential therapeutic applications.
Career Highlights
Throughout his career, Runyon has been associated with esteemed institutions such as the Research Triangle Institute and the United States of America, as represented by the Secretary of the Department of Health and Human Services. His work has significantly contributed to the understanding and development of new receptor-targeting therapeutics, playing a pivotal role in advancing medical science.
Collaborations
Scott has collaborated with notable researchers, including James Barnwell Thomas and Sanju Narayanan. These partnerships have fostered a rich environment for innovation, leading to the development of crucial technologies and therapeutics aimed at improving human health.
Conclusion
Scott P. Runyon exemplifies the spirit of innovation in the pharmaceutical field with his extensive patent portfolio and collaborations. His contributions, particularly in the realm of apelin receptor agonists, demonstrate his commitment to enhancing therapeutic options available for various health conditions. As advancements continue to unfold, Runyon's work remains at the forefront of scientific discovery.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile